A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Study identifier:D419QC00002

ClinicalTrials.gov identifier:NCT02937818

EudraCT identifier:2016-001202-42

CTIS identifier:N/A

Study Complete

Official Title

A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Medical condition

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib

Sex

All

Actual Enrollment

72

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 28 Nov 2016
Primary Completion Date: 22 Jun 2020
Study Completion Date: 27 Nov 2023

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria